HER2/EGFR in Cancer Research -- 专题文献

专题：HER2/EGFR in Cancer Research

This cluster of papers focuses on the use of HER2-targeted therapies, such as trastuzumab and pertuzumab, in the treatment of HER2-positive breast cancer. It explores the mechanisms of action, resistance, and combination therapies involving chemotherapy and monoclonal antibodies. The cluster also delves into the role of EGFR, neuregulin 1, and ADAM metalloproteinases in HER2 signaling and breast cancer progression.

专题：HER2/EGFR in Cancer Research

最新文献

Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01.

Lessons learned in linking PROTACs from discovery to the clinic

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer

New Frontiers in ADC Analysis: Advances in Chromatography, Electrophoresis, and Mass Spectrometry

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Tumor microenvironment–targeted PROTAC nanoparticle self-assembly broadly predicted by structural descriptors

Imlunestrant: First Approval

Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study

近5年高被引文献